The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Inayat, M. S., Damodaran, C., Mohiuddin, M., Elford, H. L., Gallicchio, V. S., & Ahmed, M. M. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.1.5.174 · Cited by 100
RetractedAntitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Clinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517
Hideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,508
Self-citationProteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,477
How Proteolysis Drives the Cell Cycle
King, R. W., Deshaies, R. J., Peters, J.-M., & Kirschner, M. W. (1996) · Science · doi:10.1126/science.274.5293.1652 · Cited by 1,273
Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.699 · Cited by 1,192
Proteasome inhibitors: from research tools to drug candidates
Kisselev, A. F., & Goldberg, A. L. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00056-4 · Cited by 1,184
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602223340802 · Cited by 1,081
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.-T., Lin, B., Podar, K., Gupta, D., Chauhan, D., et al. (2001) · Blood · doi:10.1182/blood.v98.1.210 · Cited by 913
Self-citationDamiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A., & Dalton, W. S. (1999) · Blood · doi:10.1182/blood.v93.5.1658 · Cited by 901
NF-κB as a Therapeutic Target in Multiple Myeloma
Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200360200 · Cited by 893
Self-citationHideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Self-citationMajor, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H. D., Yunus, F., Bell, R., Body, J., Quebe-Fehling, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.558 · Cited by 858
Multiple myeloma: evolving genetic events and host interactions
Kuehl, W. M., & Bergsagel, P. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc746 · Cited by 818
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Self-citationMolecular sequelae of proteasome inhibition in human multiple myeloma cells
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Treon, S. P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202445099 · Cited by 741
Self-citationMitsiades, N., Mitsiades, C. S., Richardson, P. G., Poulaki, V., Tai, Y.-T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1768 · Cited by 697
Self-citationMultiple myeloma; a review of 26 cases.
Harnagel, E. E., Kleinberg, I., Kahlstrom, S. C., & Rhudy, F. V. (1957) · PubMed · Cited by 682
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.12.4525 · Cited by 669
Self-citationVacca, A., Ribatti, D., Presta, M., Minischetti, M., Iurlaro, M., Ria, R., Albini, A., Bussolino, F., & Dammacco, F. (1999) · Blood · doi:10.1182/blood.v93.9.3064 · Cited by 599
Dankbar, B., Padró, T., Leo, R., Feldmann, B., Kropff, M., Mesters, R. M., Serve, H., Berdel, W. E., & Kienast, J. (2000) · Blood · doi:10.1182/blood.v95.8.2630 · Cited by 566
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
Hideshima, T., Mitsiades, C., Akiyama, M., Hayashi, T., Chauhan, D., Richardson, P., Schlossman, R., Podar, K., Munshi, N. C., Mitsiades, N., et al. (2003) · Blood · doi:10.1182/blood-2002-08-2543 · Cited by 566
Self-citationChauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T., & Anderson, K. (1996) · Blood · doi:10.1182/blood.v87.3.1104.bloodjournal8731104 · Cited by 563
Self-citationGupta, D., Treon, S., Shima, Y., Hideshima, T., Podar, K., Tai, Y., Lin, B., Lentzsch, S., Davies, F., Chauhan, D., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402295 · Cited by 553
Self-citationFermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Berenson, J. R., Hillner, B. E., Kyle, R. A., Anderson, K., Lipton, A., Yee, G. C., & Biermann, J. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.037 · Cited by 542
Self-citationBarlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., Badros, A., Zangari, M., Anaissie, E., Epstein, J., et al. (2001) · Blood · doi:10.1182/blood.v98.2.492 · Cited by 541
Kato, K., Cox, A. D., Hisaka, M. M., Graham, S. M., Buss, J. E., & Der, C. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.14.6403 · Cited by 540
Klauber, N., Parangi, S., Flynn, E. A., Hamel, E., & D’Amato, R. J. (1997) · PubMed · Cited by 524
Pearse, R. N., Sordillo, E. M., Yaccoby, S., Wong, B. R., Liau, D. F., Colman, N., Michaeli, J., Epstein, J., & Choi, Y. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201394498 · Cited by 518
Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.
Bellamy, W. T., Richter, L., Frutiger, Y. M., & Grogan, T. M. (1999) · PubMed · Cited by 515
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma
Hideshima, T., Nakamura, N., Chauhan, D., & Anderson, K. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204833 · Cited by 478
Self-citationInhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity
Keifer, J. A., Guttridge, D. C., Ashburner, B. P., & Jr.Baldwin, A. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100938200 · Cited by 478
The proteasome inhibitor PS-341 in cancer therapy.
Teicher, B. A., Ara, G., Herbst, R. S., Palombella, V. J., & Adams, J. (1999) · PubMed · Cited by 472
Pasquali, S., Maqueo, J. D., Vela, J. E., Kyle, R. A., Leong, T. L., Fritz, E., Suciu, S., PALVA, I. P., Oivanen, T. M., Corrado, C., et al. (1998) · Journal of Clinical Oncology · Cited by 470
Mitsiades, C. S., Mitsiades, N., Poulaki, V., Schlossman, R., Akiyama, M., Chauhan, D., Hideshima, T., Treon, S. P., Munshi, N. C., Richardson, P. G., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205664 · Cited by 464
Self-citationLeBlanc, R., Catley, L. P., Hideshima, T., Lentzsch, S., Mitsiades, C. S., Mitsiades, N., Neuberg, D. S., Goloubeva, O. G., Pien, C. S., Adams, J., et al. (2002) · PubMed · Cited by 450
Self-citationKarp, J. E., Lancet, J. E., Kaufmann, S. H., End, D. W., Wright, J. J., Bol, K., Horak, I., Tidwell, M. L., Liesveld, J., Kottke, T. J., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3361 · Cited by 443
Effects of Thalidomide and Related Metabolites in a Mouse Corneal Model of Neovascularization
KENYON, B. M., BROWNE, F., & D'AMATO, R. J. (1997) · Experimental Eye Research · doi:10.1006/exer.1997.0292 · Cited by 440
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3832 · Cited by 433
Uchiyama, H., Barut, B., Mohrbacher, A., Chauhan, D., & Anderson, K. (1993) · Blood · doi:10.1182/blood.v82.12.3712.3712 · Cited by 418
Self-citationGiuliani, N., Bataille, R., Mancini, C., Lazzaretti, M., & Barillé, S. (2001) · Blood · doi:10.1182/blood.v98.13.3527 · Cited by 415
Podar, K., Tai, Y.-T., Davies, F. E., Lentzsch, S., Sattler, M., Hideshima, T., Lin, B. K., Gupta, D., Shima, Y., Chauhan, D., et al. (2001) · Blood · doi:10.1182/blood.v98.2.428 · Cited by 415
Self-citationChoi, S. J., Cruz, J. C., Craig, F., Chung, H., Devlin, R. D., Roodman, G. D., & Alsina, M. (2000) · Blood · doi:10.1182/blood.v96.2.671 · Cited by 408
D'Amato, R. J., Lin, C. M., Flynn, E., Folkman, J., & Hamel, E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3964 · Cited by 406
IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade
Ogata, A., Chauhan, D., Teoh, G., Treon, S. P., Urashima, M., Schlossman, R. L., & Anderson, K. C. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.5.2212 · Cited by 399
Self-citationHideshima, T., Chauhan, D., Schlossman, R., Richardson, P., & Anderson, K. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204623 · Cited by 394
Self-citationMitsiades, C. S., Treon, S. P., Mitsiades, N., Shima, Y., Richardson, P., Schlossman, R., Hideshima, T., & Anderson, K. C. (2001) · Blood · doi:10.1182/blood.v98.3.795 · Cited by 392
Self-citationRandomised, placebo-controlled multicentre trial of clodronate in multiple myeloma
Lahtinen, R., Laakso, M., Palva, I., Elomaa, I., & Virkkunen, P. (1992) · The Lancet · doi:10.1016/0140-6736(92)93075-x · Cited by 385
Allogeneic Bone Marrow Transplantation in Multiple Myeloma
Gahrton, G., Tura, S., Ljungman, P., Belanger, C., Brandt, L., Cavo, M., Facon, T., Granena, A., Gore, M., Gratwohl, A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251802 · Cited by 378
Production of Lymphotoxin, a Bone-Resorbing Cytokine, by Cultured Human Myeloma Cells
Garrett, I. R., Durie, B. G. M., Nedwin, G. E., Gillespie, A., Bringman, T., Sabatini, M., Bertolini, D. R., & Mundy, G. R. (1987) · New England Journal of Medicine · doi:10.1056/nejm198708273170902 · Cited by 373
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma
Bergsagel, P. L., Chesi, M., Nardini, E., Brents, L. A., Kirby, S. L., & Kuehl, W. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13931 · Cited by 367
Biologic sequelae of nuclear factor–κB blockade in multiple myeloma: therapeutic applications
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.11.4079 · Cited by 367
Self-citationSampaio, E. P., Kaplan, G., Miranda, A., Nery, J. A. C., Miguel, C. P., Viana, S. M., & Sarno, E. N. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/168.2.408 · Cited by 366
Kapahi, P., Takahashi, T., Natoli, G., Adams, S. R., Chen, Y., Tsien, R. Y., & Karin, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m007204200 · Cited by 359
Shao, W., Fanelli, M., Ferrara, F. F., Riccioni, R., Rosenauer, A., Davison, K., Lamph, W. W., Waxman, S., Pelicci, P. G., Lo Coco, F., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.2.124 · Cited by 344
Hazlehurst, L. A., Damiano, J. S., Buyuksal, I., Pledger, W. J., & Dalton, W. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203782 · Cited by 344
Gahrton, G., Svensson, H., Cavo, M., Apperley, J., Bacigalupo, A., Björkstrand, B., Bladé, J., Cornelissen, J., De Laurenzi, A., Facon, T., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02726.x · Cited by 340
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients
Fonseca, R., Blood, E. A., Oken, M. M., Kyle, R. A., Dewald, G. W., Bailey, R. J., Van Wier, S. A., Henderson, K. J., Hoyer, J. D., Harrington, D., et al. (2002) · Blood · doi:10.1182/blood.v99.10.3735 · Cited by 340
Gregory, W. M., Richards, M. A., & Malpas, J. S. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.334 · Cited by 338
Han, J.-H., Choi, S. J., Kurihara, N., Koide, M., Oba, Y., & Roodman, G. D. (2001) · Blood · doi:10.1182/blood.v97.11.3349 · Cited by 328
Park, W. H., Seol, J. G., Kim, E.-K., Hyun, J. M., Jung, C. W., Lee, C. R., Kim, B.-K., & Lee, Y. Y. (2000) · PubMed · Cited by 322
Desikan, R., Barlogie, B., Sawyer, J., Ayers, D., Tricot, G., Badros, A., Zangari, M., Munshi, N. C., Anaissie, E., Spoon, D., et al. (2000) · Blood · doi:10.1182/blood.v95.12.4008 · Cited by 320
Bakkus, M., Heirman, C., Van Riet, I., Van Camp, B., & Thielemans, K. (1992) · Blood · doi:10.1182/blood.v80.9.2326.2326 · Cited by 314
Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Geneviève, F., Zandecki, M., Laı̈, J.-L., Leleu, X., Jouet, J.-P., Bauters, F., et al. (2001) · Blood · doi:10.1182/blood.v97.6.1566 · Cited by 312
Lenhoff, S., Hjorth, M., Holmberg, E. C., Turesson, I., Westin, J., Nielsen, J. L., Wislöff, F., Brinch, L., Carlson, K. E., Carlsson, M. S., et al. (2000) · PubMed · doi:10.1182/blood.v95.1.7 · Cited by 310
Orlowski, R. Z., Eswara, J. R., Lafond-Walker, A., Grever, M. R., Orłowski, M., & Dang, C. V. (1998) · PubMed · Cited by 275
Chauhan, D., Kharbanda, S., Ogata, A., Urashima, M., Teoh, G., Robertson, M., Kufe, D. W., & Anderson, K. C. (1997) · Blood · doi:10.1182/blood.v89.1.227 · Cited by 272
Self-citationInterleukin-6 Inhibits Apoptosis of Malignant Plasma Cells
Lichtenstein, A., Tu, Y., Fady, C., Vescio, R., & Berenson, J. (1995) · Cellular Immunology · doi:10.1006/cimm.1995.1076 · Cited by 271
Ascorbic acid enhances arsenic trioxide–induced cytotoxicity in multiple myeloma cells
Grad, J. M., Bahlis, N. J., Reis, I., Oshiro, M. M., Dalton, W. S., & Boise, L. H. (2001) · Blood · doi:10.1182/blood.v98.3.805 · Cited by 271
Yaccoby, S., Barlogie, B., & Epstein, J. (1998) · Blood · doi:10.1182/blood.v92.8.2908 · Cited by 255
Kröger, N., Schwerdtfeger, R., Kiehl, M., Sayer, H. G., Renges, H., Zabelina, T., Fehse, B., Tögel, F., Wittkowsky, G., Kuse, R., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0131 · Cited by 255
Puthier, D., Bataille, R., & Amiot, M. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199912)29:12<3945::aid-immu3945>3.0.co;2-o · Cited by 254
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells.
Standal, T., Seidel, C., Hjertner, Ø., Plesner, T., Sanderson, R. D., Waage, A., Borset, M., & Sundan, A. (2002) · Blood · doi:10.1182/blood-2002-04-1190 · Cited by 244
Serum syndecan-1: a new independent prognostic marker in multiple myeloma
Seidel, C., Sundan, A., Hjorth, M., Turesson, I., Dahl, I. M. S., Abildgaard, N., Waage, A., & Børset, M. (2000) · Blood · doi:10.1182/blood.v95.2.388 · Cited by 239
Tu, Y., Gardner, A. M., & Lichtenstein, A. K. (2000) · PubMed · Cited by 235
Rousselot, P. H., Labaume, S., Marolleau, J., Larghero, J., Noguera, M., Brouet, J. C., & Fermand, J. (1999) · PubMed · Cited by 225
P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy
Grogan, T., Spier, C., Salmon, S., Matzner, M., Rybski, J., Weinstein, R., Scheper, R., & Dalton, W. (1993) · Blood · doi:10.1182/blood.v81.2.490.490 · Cited by 207
Chauhan, D., Hideshima, T., Rosen, S., Reed, J. C., Kharbanda, S., & Anderson, K. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100074200 · Cited by 202
Self-citationSTI571: A Paradigm of New Agents for Cancer Therapeutics
Mauro, M. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.325 · Cited by 202
Derenne, S., Amiot, M., Barillé, S., Collette, M., Robillard, N., Berthaud, P., Harousseau, J.-L., & Bataille, R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.12.2048 · Cited by 195
Badros, A., Barlogie, B., Morris, C., Desikan, R., Martin, S. R., Munshi, N., Zangari, M., Mehta, J., Toor, A., Cottler-Fox, M., et al. (2001) · Blood · doi:10.1182/blood.v97.9.2574 · Cited by 186
Chauhan, D., Pandey, P., Hideshima, T., Treon, S., Raje, N., Davies, F. E., Shima, Y., Tai, Y.-T., Rosen, S., Avraham, S., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003428200 · Cited by 185
Self-citationProduction of interleukin-1 by bone marrow myeloma cells
Cozzolino, F., Torcia, M., Aldinucci, D., Rubartelli, A., Miliani, A., Shaw, A., Lansdorp, P., & Di Guglielmo, R. (1989) · Blood · doi:10.1182/blood.v74.1.380.380 · Cited by 185
Epling-Burnette, P. K., Zhong, B., Bai, F., Jiang, K., Bailey, R. D., Garcia, R., Jove, R., Djeu, J. Y., Loughran, T. P., & Wei, S. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7486 · Cited by 181
Podar, K., Tai, Y.-T., Lin, B. K., Narsimhan, R. P., Sattler, M., Kijima, T., Salgia, R., Gupta, D., Chauhan, D., & Anderson, K. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109068200 · Cited by 180
Self-citationInsulin-like growth factor I is a dual effector of multiple myeloma cell growth
Ge, N.-L., & Rudikoff, S. (2000) · Blood · doi:10.1182/blood.v96.8.2856 · Cited by 175
Wei, L.-H., Kuo, M.-L., Chen, C.-A., Chou, C.-H., Cheng, W.-F., Chang, M.-C., Su, J.-L., & Hsieh, C.-Y. (2001) · Oncogene · doi:10.1038/sj.onc.1204733 · Cited by 174
Interleukin-21 is a growth and survival factor for human myeloma cells
Brenne, A.-T., Baade Ro, T., Waage, A., Sundan, A., Borset, M., & Hjorth-Hansen, H. (2002) · Blood · doi:10.1182/blood.v99.10.3756 · Cited by 168
Anderson, K. (2003) · European Journal of Haematology · doi:10.1034/j.1600-0609.2003.01067.x · Cited by 168
Self-citationFerlin, M., Noraz, N., Hertogh, C., Brochier, J., Taylor, N. N., & Klein, B. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02364.x · Cited by 156
The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.
Hideshima, T., Chauhan, D., Hayashi, T., Podar, K., Akiyama, M., Gupta, D., Richardson, P. G. G., Munshi, N. C., & Anderson, K. C. (2002) · PubMed · Cited by 155
Self-citationQiang, Y., Kopantzev, E. P., & Rudikoff, S. (2002) · Blood · doi:10.1182/blood.v99.11.4138 · Cited by 150
Massaia, M., Borrione, P., Battaglio, S., Mariani, S., Beggiato, E., Napoli, P., Voena, C., Bianchi, A., Coscia, M., Besostri, B., et al. (1999) · Blood · doi:10.1182/blood.v94.2.673 · Cited by 149
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Anderson, K. C., & Treon, S. P. (2002) · Blood · doi:10.1182/blood.v99.6.2162 · Cited by 148
Self-citationHayashi, T., Hideshima, T., Akiyama, M., Richardson, P. G. G., Schlossman, R. L., Chauhan, D., Munshi, N. C., Waxman, S., & Anderson, K. C. (2002) · PubMed · Cited by 148
Self-citationTeoh, G., & Anderson, K. C. (1997) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70413-5 · Cited by 146
Self-citationProteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia.
Tan, C., & Waldmann, T. A. (2002) · PubMed · Cited by 140
Vescio, R. A., Cao, J., Hong, C. H., Lee, J. C., Wu, C. H., DerDanielian, M., Wu, V., Newman, R., Lichtenstein, A. K., & Berenson, J. R. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.5.2487 · Cited by 133
Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials
Falardeau, P., Champagne, P., Poyet, P., Hariton, C., & Dupont, �. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90035-1 · Cited by 123
Oyajobi, B. O., Anderson, D. M., Traianedes, K., Williams, P. J., Yoneda, T., & Mundy, G. R. (2001) · PubMed · Cited by 119
2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells
Chauhan, D., Catley, L. P., Hideshima, T., Li, G., LeBlanc, R., Gupta, D. K., Sattler, M., Richardson, P. G. G., Schlossman, R. L., Podar, K., et al. (2002) · Blood · doi:10.1182/blood-2002-02-0376 · Cited by 117
Self-citationRAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells
Chauhan, D., Hideshima, T., Pandey, P., Treon, S. P., Teoh, G., Raje, N. S., Rosen, S. T., Krett, N. L., Husson, H., Avraham, S., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1203082 · Cited by 113
Self-citationCurrent status of clinical trials of farnesyltransferase inhibitors
Karp, J. E., Kaufmann, S. H., Adjei, A. A., Lancet, J. E., Wright, J. J., & End, D. W. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00009 · Cited by 112
Hjertner, Ø., Torgersen, M. L., Seidel, C., Hjorth‐Hansen, H., Waage, A., Børset, M., & Sundan, A. (1999) · Blood · doi:10.1182/blood.v94.11.3883 · Cited by 111
Freund, G. G., Kulas, D. T., & Mooney, R. A. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.4.1811 · Cited by 111
Current Therapy for Multiple Myeloma
Rajkumar, S. V., Gertz, M. A., Kyle, R. A., & Greipp, P. R. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.8.813 · Cited by 107
Sawyer, J. R., Lukacs, J. L., Thomas, E. L., Swanson, C., Goosen, L. S., Sammartino, G., Gilliland, J. C., Munshi, N., Tricot, G., Shaughnessy, J., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02546.x · Cited by 96
Adjei, A. A., Davis, J. N., Bruzek, L. M., Erlichman, C., & Kaufmann, S. H. (2001) · PubMed · Cited by 95
Tricot, G. J. K., Spencer, T., Sawyer, J. R., Spoon, D., Desikan, R. K., Fassas, A., Badros, A. Z., Zangari, M., Munshi, N. C., Anaissie, E. J., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03231.x · Cited by 89
S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.
Lentzsch, S., Rogers, M. S., LeBlanc, R., Birsner, A. E., Shah, J. H., Treston, A. M., Anderson, K. C., & D’Amato, R. J. (2002) · PubMed · Cited by 88
Self-citationSTI571: A Paradigm of New Agents for Cancer Therapeutics
Mauro, M. J., O'Dwyer, M. E., Heinrich, M. C., & Druker, B. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.1.325 · Cited by 87
Lacy, M. Q., Donovan, K. A., Heimbach, J. K., Ahmann, G. J., & Lust, J. A. (1999) · Blood · doi:10.1182/blood.v93.1.300 · Cited by 81
Barillé‐Nion, S., Bataille, R., Rapp, M., Harousseau, J., & Amiot, M. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5723 · Cited by 80
Sonneveld, P., Schoester, M., & Leeuw, K. D. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1584 · Cited by 80
Chauhan, D., Li, G., Auclair, D., Hideshima, T., Richardson, P. G. G., Podar, K., Mitsiades, N., Mitsiades, C. S., Li, C., Kim, R. S., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3146 · Cited by 78
Self-citationOgawa, M., Nishiura, T., Oritani, K., Yoshida, H., Yoshimura, M., Okajima, Y., Ishikawa, J., Hashimoto, K., Matsumura, I., Tomiyama, Y., et al. (2000) · PubMed · Cited by 74
Deaglio, S., Canella, D., Baj, G., Arnulfo, A., Waxman, S., & Malavasi, F. (2001) · Leukemia Research · doi:10.1016/s0145-2126(00)00105-3 · Cited by 66
Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice
Kotoh, T., Dhar, D. K., Masunaga, R., Tabara, H., Tachibana, M., Kubota, H., Kohno, H., & Nagasue, N. (1999) · Surgery · doi:10.1016/s0039-6060(99)70206-0 · Cited by 65
Béliveau, R., Gingras, D., Kruger, E. A., Lamy, S., Sirois, P., Simard, B., Sirois, M. G., Tranqui, L., Baffert, F., Beaulieu, É., et al. (2002) · PubMed · Cited by 65
Randomized trial experience of the Intergroupe Francophone du My[eacute]lome
Attal, M., & Harousseau, J. (2001) · Seminars in Hematology · doi:10.1016/s0037-1963(01)90014-9 · Cited by 51
Thalidomide: A novel template for anticancer drugs
Stirling, D. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90032-6 · Cited by 50
Targeted therapy for multiple myeloma
Anderson, K. C. (2001) · Seminars in Hematology · doi:10.1016/s0037-1963(01)90021-6 · Cited by 47
Self-citationJing, Y., Xia, L., & Waxman, S. (2002) · Blood · doi:10.1182/blood.v100.3.1008 · Cited by 34
Cited by
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationLenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,296
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
Self-citationBiological properties of “naked” metal nanoparticles☆
BHATTACHARYA, R., & MUKHERJEE, P. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.013 · Cited by 917
Metadata
- Authors
- Hideshima, T., & Anderson, K. C.
- Venue
- Nature Reviews Cancer
- Published
- 2002-12
- Volume
- 2
- Issue
- 12
- Pages
- 927-937
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1977348505
- Cited by
- 425
- References
- 128
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.